Podcasts about research roundup

Send us a Text Message.In this first edition of our special Research Round-Up series, we dive into groundbreaking research that examines a novel way to put adolescent & young adult (AYA) survivors BACK in the driver's seat of their care.Dr. Kelly Martin, physical therapist & TheOncoPT team member, joins Elise to discuss the importance of education and bridging the gap in AYA cancer care by leveraging social media.Even if you despise social media, you DO NOT want to miss this episode because...  ⬇️YOUR PATIENTS ARE ON SOCIAL MEDIA & ARE USING IT TO EDUCATE THEMSELVES.Therefore, it is YOUR responsibility to help your patients find accurate, reliable, helpful education online.To find out where to start, listen to our conversation now! Join TheOncoPT Specialization Community here. Today's Research Round-up Article: Partnering With Social Media Influencers to Equitably Improve Adolescent and Young Adult Cancer Outcomes: A Novel Strategy to Support Cancer Care DeliveryWriting your oncology specialty exam case report is a huge undertaking.And it's easy to make silly mistakes that can derail your entire writing process.That's why you need my brand new FREE masterclass: The 3 Step Framework for a Finished Case ReportSave your seat at TheOncoPT.com/frameworkFollow TheOncoPT on Instagram.Follow TheOncoPT on TikTok.Follow TheOncoPT on Twitter.

This episode highlights three recent articles from the field of musical acoustics. First, we talk to Elvira Brattico (Aarhus University) about her research into what causes a person to experience music as noise. Next, Stefan Weinzierl (Technical University of Berlin) discusses how a musician's movement during a performance will impact the notes listeners hear. Finally, Pablo Miranda Valiente (University of Southampton) discusses his work to develop a model that shows the impact a piano soundboard has on the note played. Associated papers: - Giulio Carraturo, Marina Kliuchko, and Elvira Brattico. "Loud and unwanted: Individual differences in the tolerance for exposure to music."  J. Acoust. Soc. Am. 155, 3274–3282 (2024). https://doi.org/10.1121/10.0025924.- David Ackermann, Fabian Brinkmann, and Stefan Weinzierl. "Musical instruments as dynamic sound sources." J. Acoust. Soc. Am. 155, 2302–2313 (2024). https://doi.org/10.1121/10.0025463.- Pablo Miranda Valiente, Giacomo Squicciarini, and David J. Thompson. "Influence of soundboard modelling approaches on piano string vibration." J. Acoust. Soc. Am. 155, 3213–3232 (2024). https://doi.org/10.1121/10.0025925.Read more from The Journal of the Acoustical Society of America (JASA).Learn more about Acoustical Society of America Publications.Music Credit: Min 2019 by minwbu from Pixabay. 

Join Chief U.S. Economist Lara Rhame, Director of Investment Research Andrew Korz and Research Associate Alan Flannigan as they examine their outlooks for corporate credit, private equities, commercial real estate and key macroeconomic trends for Q3 2024. They go in depth on the latest impacts of market concentration, stubborn inflation and more, with a look at the causes and potential implications of the optimism currently priced into markets. 

In this episode Alex R. Kemper, MD, MPH, MS, FAAP, deputy editor of the journal Pediatrics, offers a bird's-eye view of the July issue. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Lisa Abuogi, MD, FAAP, about how to counsel people living with HIV who want to breastfeed their babies. For resources go to aap.org/podcast.

This week we set the episode timer for 15 minutes, and managed to get through just five papers before the buzzer went off! So we have plenty more papers to discuss in future episodes... ENHANCING K-12 STUDENTS' PERFORMANCE IN CHEMISTRY THROUGH CHATGPT-POWERED BLENDED LEARNING IN THE EDUCATION 4.0 ERA https://library.iated.org/view/ORTIZDEZARATE2024ENH   Empowering student self-regulated learning and science education through ChatGPT: A pioneering pilot study https://bera-journals.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjet.13454   ChatGPT “contamination”: estimating the prevalence of LLMs in the scholarly literature https://arxiv.org/abs/2403.16887   Monitoring AI-Modified Content at Scale: A Case Study on the Impact of ChatGPT on AI Conference Peer Reviews https://arxiv.org/abs/2403.07183   Large language models are able to downplay their cognitive abilities to fit the persona they simulate https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0298522  

In this episode Rachel Moon, MD, FAAP, associate editor of digital media for the journal Pediatrics, shares a research roundup from the June issue. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also talk to Edith Bracho-Sanchez, MD, FAAP, about her role as host of Healthy Children, a new AAP podcast geared toward parents. For resources go to aap.org/podcast.

Send us a Text Message.Did you know that dyslexic kids are more likely to have problems with motor skills? We didn't either! Join us as we review three recent scientific papers about dyslexia.Here are the three papers from the show:Decarli, G, et al. “Motor Skills and Capacities in Developmental Dyslexia: A Systematic Review and Meta-Analysis.” Acta Psychologica, North-Holland, 20 Apr. 2024, www.sciencedirect.com/science/article/pii/S000169182400146X. Stein, John. “Theories about Developmental Dyslexia.” MDPI, Brain Sciences, 26 Jan. 2023, www.mdpi.com/2076-3425/13/2/208. Yu, Xi, et al. “Patterns of Neural Functional Connectivity in Infants at Familial Risk of Developmental Dyslexia.” JAMA Network Open, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/36301547/. Accessed 10 May 2024.This episode is sponsored by My Phone Number Song. Enter a phone number and get a fully-produced earworm with that number as the lyrics! Dyslexia Journey has conversations and explorations to help you support the dyslexic child in your life. Content includes approaches, tips, and interviews with a range of guests from psychologists to educators to people with dyslexia. Increase your understanding and connection with your child as you help them embrace their uniqueness and thrive on this challenging journey!Also check out our YouTube channel! https://www.youtube.com/@ParentingDyslexiaJourney

In this episode Lewis First, MD, MS, FAAP, editor-in-chief of Pediatrics, is back for “First Up.” He offers a bird's-eye view of what's in the May issue of the journal. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with David Kimberlin, MD, FAAP, editor of the Red Book, about what to expect in the 2024 edition released this month. For resources go to aap.org/podcast.

In the first episode of a new podcast series from Radix Research, co-hosts Chris Nebenzahl and Jay Denton cover the key trends impacting multifamily in April. They also take a deep dive into the recently released April jobs report and discuss the Fed meeting which wrapped up last week. To close out the pod they leave things on a light note and share their predictions for the Kentucky Derby!Check out the Radix Research Roundup, our newest weekly podcast series!

One of the most important things to learn about a pest before trying to manage for it, is to learn its lifecycle and assess the economic damage it can do. Jeremy Irvine, masters student with the University of Saskatchewan, is working on this important information for an uncommon pest: the lesser clover leaf weevil. Mainly... Read More

Welcome to BCI Cattle Chat! In this episode the experts discuss what do when a bull doesn't pass a bull BSE and answer some economic questions. Guest Dannell Kopp also discuss her research about metaphylaxis. Guest: Dannell Kopp, Graduate and Veterinary Student 2:21 Bull BSE 10:47 Economic Questions 14:00 Research Roundup: Metaphylaxis For more on… Continue reading Bull BSE, Economic Questions, Research Roundup: Metaphylaxis

The first quarter was marked by a continuation of last year's economic optimism, albeit against the backdrop of stubborn inflation and high rates. While many investors still dream about substantial rate cuts, a return to the “old normal” could require investors to adjust.Join Director of Investment Research Andrew Korz and Chief U.S. Economist Lara Rhame as they examine CRE pressures, movements in equities, and the balance of challenges and optimism in their outlooks for macro and markets in Q2. 

In this episode Alex R. Kemper, MD, MPH, MS, FAAP, deputy editor of the journal Pediatrics offers a bird's-eye view of the April issue. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Samantha Ahdoot, MD, FAAP, about the effects of global climate change on children's health. For resources go to aap.org/podcast.

Welcome to BCI Cattle Chat! In this episode the experts discuss should you keep females out of first calf heifers and offspring being on the maternal side. Guest Katie Long discusses her research about combination therapy. We Want to Hear From YouThe Beef Cattle Institute team would like to hear your thoughts about the Cattle… Continue reading Should you Keep Females from First Calf Heifers, Offspring Being Open, Research Roundup

The season-ending episode for Series 7, this is the fifteenth in the series that started on 1st November last year with the "Regeneration: Human Centred Educational AI" episode. And it's an unbelievable 87th episode for the podcast (which started in September 2019). When we come back with Series 8 after a short break for Easter, we're going to take a deeper dive into two specific use cases for AI in Education. The first we'll discuss is Assessment, where there's both a threat and opportunity created by AI. And the second topic is AI Tutors, where there's more of a focus on how we can take advantage of the technology to help improve support for learning for students. This episode looks at one key news announcement - the EU AI Act - and a dozen new research papers on AI in education. News EU AI Act https://www.europarl.europa.eu/news/en/press-room/20240308IPR19015/artificial-intelligence-act-meps-adopt-landmark-law The European Parliament approved the AI Act on 13 March and there's some stuff in here that would make good practice guidance. And if you're developing AI solutions for education, and there's a chance that one of your customers or users might be in the EU, then you're going to need to follow these laws (just like GDPR is an EU law, but effectively applies globally if you're actively offering a service to EU residents). The Act bans some uses of AI that threaten citizen's rights - such as social scoring and biometric identification at mass level (things like untargeted facial scanning of CCTV or internet content, emotion recognition in the workplace or schools, and AI built to manipulate human behaviour) - and for the rest it relies on regulation according to categories.  High Risk AI systems have to be assessed before being deployed and throughout their lifecycle. In the High Risk AI category it includes critical infrastructure (like transport and energy), product safety, law enforcement, justice and democratic processes, employment decision making - and Education. So decision making using AI in education needs to do full risk assessments, maintain usage logs, be transparent and accurate - and ensure human oversight. Examples of decision making that would be covered would be things like exam scoring, student recruitment screening, or behaviour management. General generative AI - like chatgpt or co-pilots - will not be classified as high risk, but they'll still have obligations under the Act to do things like clear labelling for AI generated image, audio and video content ; make sure there's it can't generate illegal content, and also disclose what copyright data was used for training. But, although general AI may not be classified as high risk, if you then use that to build a high risk system - like an automated exam marker for end-of-school exams, then this will be covered under the high risk category. All of this is likely to become law by the middle of the year, and by the end of 2024 prohibited AI systems will be banned - and by mid-2025 the rules will start applying for other AI systems. ResearchAnother huge month. I spent the weekend reviewing a list of 350 new papers published in the first two weeks of March, on Large Language Models, ChatGPT etc, to find the ones that are really interesting for the podcast Adapting Large Language Models for Education: Foundational Capabilities, Potentials, and Challenges arXiv:2401.08664   A Study on Large Language Models' Limitations in Multiple-Choice Question Answering arXiv:2401.07955   Dissecting Bias of ChatGPT in College Major Recommendations arXiv:2401.11699   Evaluating Large Language Models in Analysing Classroom Dialogue arXiv:2402.02380    The Future of AI in Education: 13 Things We Can Do to Minimize the Damage https://osf.io/preprints/edarxiv/372vr   Scaling the Authoring of AutoTutors with Large Language Models https://arxiv.org/abs/2402.09216   Role-Playing Simulation Games using ChatGPT https://arxiv.org/abs/2402.09161   Economic and Financial Learning with Artificial Intelligence: A Mixed-Methods Study on ChatGPT https://arxiv.org/abs/2402.15278   A Study on the Vulnerability of Test Questions against ChatGPT-based Cheating https://arxiv.org/abs/2402.14881   Incorporating Artificial Intelligence Into Athletic Training Education: Developing Case-Based Scenarios Using ChatGPT https://meridian.allenpress.com/atej/article/19/1/42/498456   Incorporating Artificial Intelligence Into Athletic Training Education: Developing Case-Based Scenarios Using ChatGPT https://meridian.allenpress.com/atej/article/19/1/42/498456   RECIPE4U: Student-ChatGPT Interaction Dataset in EFL Writing Education https://arxiv.org/abs/2403.08272   Comparison of the problem-solving performance of ChatGPT-3.5, ChatGPT-4, Bing Chat, and Bard for the Korean emergency medicine board examination question bank https://journals.lww.com/md-journal/fulltext/2024/03010/comparison_of_the_problem_solving_performance_of.48.aspx?context=latestarticles   Comparing the quality of human and ChatGPT feedback of students' writing https://www.sciencedirect.com/science/article/pii/S0959475224000215          

Welcome to BCI Cattle Chat!  Please click on any links below to be taken to sources mentioned in the podcast. Keep an eye out for news regarding the podcast on Facebook, Twitter, and Instagram. 2:32 Research Round-Up: Rebecca Bigelow 9:52 Breeding Season Questions 15:20 Boosting Heifers Prior to Puberty Guest: Rebecca Bigelow, Ph.D. Student For… Continue reading Research Round-Up, Breeding Season Questions, Boosting Heifers Prior to Puberty

In this episode Rachel Moon, MD, FAAP, associate editor of digital media for the journal Pediatrics, shares a research roundup from the March issue. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also talk to Felicitas Livaudais, MD, FAAP, and Cindy Calderon, MD, FAAP, about surviving disasters and learning how to prepare for the future. For resources go to aap.org/podcast.

Mixing up the science news a bit, Dr. L runs down the titles of breaking studies and the rest of the crew reponds with gut reactions. Topics include processed foods, protein breakfasts, yo-yo dieting, kiwi for cognition, GLP-1 drugs and alcohol, taste buds and eating pace, and more. After the break, Phil talks about why he's traveling and how bringing in experts beyond one's wheelhouse is a sign of strength. -------- Donate to the show: https://www.paypal.com/donate/?hosted_button_id=3J6ZFPPKG6E6N Subscribe at Apple iTunes: https://podcasts.apple.com/us/podcast/nutritionradio-org/id1688282387  Podcast on Spotify: https://open.spotify.com/show/1ECHrnjxjn33DBNWgErPtp Subscribe to our YouTube backup: https://www.youtube.com/lonman07?sub_confirmation=1 Podcast on Amazon/ Audible: https://www.audible.com/pd/NutritionRadioorg-Podcast/B0BS8LFLLX?qid=1675812257&sr=1-1&ref=a_search_c3_lProduct_1_1&pf_rd_p=83218cca-c308-412f-bfcf-90198b687a2f&pf_rd_r=YKEZ8DX192TQF0CQV8KX&pageLoadId=u3x6bJ1 Podcast network web site: https://sites.libsyn.com/455769/site IronRadio-only site: https://www.ironradio.org/ 

It's a News and Research Episode this week    There has been a lot of AI news and AI research that's related to education since our last Rapid Rundown, so we've had to be honest and drop 'rapid' from the title! Despite talking fast, this episode still clocked in just over 40 minutes, and we really can't out what to do - should we talk less, cover less news and research, or just stop worrying about time, and focus instead on making sure we bring you the key things every episode?     News More than half of UK undergraduates say they use AI to help with essays https://www.theguardian.com/technology/2024/feb/01/more-than-half-uk-undergraduates-ai-essays-artificial-intelligence This was from a Higher Education Policy Institute of 1,000 students, where they found 53% are using AI to generate assignment material. 1 in 4 are using things like ChatGPT and Bard to suggest topics 1 in 8 are using it to create content And 1 in 20 admit to copying and pasting unedited AI-generated text straight into their assignments Finance worker pays out $25 million after video call with deepfake ‘chief financial officer' https://www.cnn.com/2024/02/04/asia/deepfake-cfo-scam-hong-kong-intl-hnk/index.html An HK-based employee of a multinational firm wired out $25M after attending a video call where all employees were deepfaked, including the CFO. He first got an email which was suspicious but then was reassured on the video call with his “coworkers.”   NSW Department of Education Launch NSW EduChat https://www.theguardian.com/australia-news/2024/feb/12/the-ai-chat-app-being-trialled-in-nsw-schools-which-makes-students-work-for-the-answers NSW are rolling out a trial to 16 public schools of a chatbot built on Open AI technology, but without giving students and staff unfettered access to ChatGPT. Unlike ChatGPT, the app has been designed to only respond to questions that relate to schooling and education, via content-filtering and topic restriction. It does not reveal full answers or write essays, instead aiming to encourage critical thinking via guided questions that prompt the student to respond – much like a teacher.   The Productivity Commission has thoughts on AI and Education https://www.pc.gov.au/research/completed/making-the-most-of-the-ai-opportunity The PC released a set of research papers about "Making the most of the AI opportunity", looking at Productivity, Regulation and Data Access. They do talk about education in two key ways: "Recent improvements in generative AI are expected to present opportunities for innovation in publicly provided services such as healthcare, education, disability and aged care, which not only account for a significant part of the Australian economy but also traditionally exhibit very low productivity growth" "A challenge for tertiary education institutions will be to keep up to date with technological developments and industry needs. As noted previously by the Commission,  short courses and unaccredited training are often preferred by businesses for developing digital and data skills as they can be more relevant and up to date, as well as more flexible"   Yes, AI-Assisted Inventions can be inventions News from the US, that may set a precedent for the rest of the world. Patents can be granted for AI-assisted inventions - including prompts, as long as there's significant contribution from the human named on the patent https://www.federalregister.gov/public-inspection/2024-02623/guidance-inventorship-guidance-on-ai-assisted-inventions   Not news, but Ray mentioned his Very British Chat bot. Sadly, you need the paid version of ChatGPT to access it as it's one of the public GPTs, but if you have that you'll find it here: Very British Chat   Sora was announced https://www.abc.net.au/news/2024-02-16/ai-video-generator-sora-from-openai-latest-tech-launch/103475830 Although it was the same day that Google announced Gemini 1.5, we led with Sora here - just like the rest of the world's media did!  On the podcast, we didn't do it justice with words, so instead here's four threads on X that are worth your time to readwatch to understand what it can do: Taking a video, and changing the style/environment: https://x.com/minchoi/status/1758831659833602434?s=20 Some phenomenally realistic videos: https://x.com/AngryTomtweets/status/1759171749738840215?s=20 (remember, despite how 'real' these videos appear, none of these places exist outside of the mind of Sora!) Bling Zoo: https://x.com/billpeeb/status/1758223674832728242?s=20 This cooking grandmother does not exist: https://x.com/sama/status/1758219575882301608?s=20 (A little bit like her mixing spoon, that appears to exist only for mixing and then doesn't)   Google's Gemini 1.5 is here…almost https://www.oneusefulthing.org/p/google-gemini-advanced-tasting-notes       Research Papers   Google's Gemini 1.5 can translate languages it doesn't know https://storage.googleapis.com/deepmind-media/gemini/gemini_v1_5_report.pdf Google also published a 58 page report on what their researchers had found with it, and we found the section on translation fascinating. Sidenote: There's an interesting Oxford Academic research project report from last year that was translating cuneiform tablets from Akkadian into English, which didn't use Large Language Models, but set the thinking going on this aspect of using LLMs   Understanding the Role of Large Language Models in Personalizing and Scaffolding Strategies to Combat Academic Procrastination arXiv:2312.13581   Challenges and Opportunities of Moderating Usage of Large Language Models in Education arXiv:2312.14969   ChatEd: A Chatbot Leveraging ChatGPT for an Enhanced Learning Experience in Higher Education arXiv:2401.00052    AI Content Self-Detection for Transformer-based Large Language Models arXiv:2312.17289   Evaluating the Performance of Large Language Models for Spanish Language in Undergraduate Admissions Exams arXiv:2312.16845   Taking the Next Step with Generative Artificial Intelligence: The Transformative Role of Multimodal Large Language Models in Science Education arXiv:2401.00832   Empirical Study of Large Language Models as Automated Essay Scoring Tools in English Composition - Taking TOEFL Independent Writing Task for Example arXiv:2401.03401   Using Large Language Models to Assess Tutors' Performance in Reacting to Students Making Math Errors arXiv:2401.03238   Future-proofing Education: A Prototype for Simulating Oral Examinations Using Large Language Models arXiv:2401.06160   How Teachers Can Use Large Language Models and Bloom's Taxonomy to Create Educational Quizzes arXiv:2401.05914   How does generative artificial intelligence impact student creativity? https://www.sciencedirect.com/science/article/pii/S2713374523000316   Large Language Models As MOOCs Graders arXiv:2402.03776    Can generative AI and ChatGPT outperform humans on cognitive-demanding problem-solving tasks in science? arXiv:2401.15081   

Welcome to BCI Cattle Chat!  Please click on any links below to be taken to sources mentioned in the podcast. Keep an eye out for news regarding the podcast on Facebook, Twitter, and Instagram. 2:23 Cattle on Feed Report 12:24 Listener Question: Hoof Care 17:32 Research Round-Up: Luis Feitoza Guest: Luis Feitoza, Graduate Research Assistant… Continue reading Cattle on Feed Report, Hoof Care, Research Round-Up

In this episode Lewis First, MD, MS, FAAP, editor-in-chief of Pediatrics, is back for “First Up.” He offers a bird's-eye view of what's in the February issue of the journal. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Steven A. Abrams, MD, FAAP, about a new clinical report on the potential dangers of artificial pesticides used on foods containing genetically modified organisms. For resources go to aap.org/podcast.

Today's episode is a recap and "roundup" of research articles that were published in December 2023. Although we cannot take one single paper and make broad-sweeping claims, I do believe there are practical considerations and takeaways for each one of the papers that I chose for the episode.The first paper tackles how lifestyle choices (even those of the father) might impact future generations. The authors of the study urge men to consider the potential shadow that paternal alcohol use has on future offspring. The research presents a compelling case for pre-conception alcohol abstinence, linking a father's drinking habits to potential birth defects due to sperm alterations. Moreover, I will discuss the surprising cognitive boosting effects of Lion's Mane mushroom in young people after one-time administration.Next, I will go over the nuances of pain-relieving medication and pregnancy health, scrutinizing recent findings on acetaminophen use in the third trimester of pregnancy and childhood outcomes. From there I will shift gears to discuss a systematic review that outlines the benefits of glycine supplementation in healthy populations, highlighting its role in enhancing sleep quality and cognitive function, along with possible implications for aging research. Lastly, the conversation goes into advances in personalized nutrition. Specifically, how fiber might be differently affecting gut bacteria, and how those same bacteria matter for what fibers it is you consume.Be sure to subscribe for future episodes covering specific nutrients and strategies for achieving optimal nutrient adequacy.Papers cited in the podcast:Paternal alcohol use: https://onlinelibrary.wiley.com/doi/10.1111/andr.13566Lions mane: https://www.mdpi.com/2072-6643/15/22/4842Acetaminophen use during pregnancy: https://www.nature.com/articles/s41390-023-02924-4Glycine: https://link.springer.com/article/10.1007/s11357-023-00970-8Fiber: https://pubmed.ncbi.nlm.nih.gov/37942526/Support the show

Here's what you need to know for today in the business of podcasting: Streaming audio twice as “authentic” than TV for advertisers. Podcasts? Nine times. by Brad HilliOS 17, a writeup by Pete BirsingerWhy Gen Z's biggest podcasters are working from bed by Lilly SmithThe 5 trends that will shape sports marketing in 2024 by Alyssa MeyersMusic streaming service SoundCloud tunes up for sale by Mark Kleinman…as for the rest of the news: Signal Hill Insights shares three potential game-changers from their 2023 research, Cumulus Media signs a deal with BiggerPockets, and iHeartMedia is launching a politically-focused podcast network.

Here's what you need to know for today in the business of podcasting: Streaming audio twice as “authentic” than TV for advertisers. Podcasts? Nine times. by Brad HilliOS 17, a writeup by Pete BirsingerWhy Gen Z's biggest podcasters are working from bed by Lilly SmithThe 5 trends that will shape sports marketing in 2024 by Alyssa MeyersMusic streaming service SoundCloud tunes up for sale by Mark Kleinman…as for the rest of the news: Signal Hill Insights shares three potential game-changers from their 2023 research, Cumulus Media signs a deal with BiggerPockets, and iHeartMedia is launching a politically-focused podcast network.

Welcome to BCI Cattle Chat!  Please click on any links below to be taken to sources mentioned in the podcast. Keep an eye out for news regarding the podcast on Facebook, Twitter, and Instagram. 2:14 Winter Feeding Plans 11:08 Cold Weather Management 17:58 Research Round-Up: Makenna Jensen Guest: Makenna Jensen, Veterinary Student and BCI Graduate… Continue reading Winter Feeding Plans, Cold Weather Management, Research Round-Up

Today hosts Katja and Tiffany dive into the importance of dynamic mobility training and its broader applications. Stretching is always a loaded topic. There are lots of different opinions and broad research available, with new research being released regularly. In this episode, we talk about the newer research on dynamic stretching and how it relates to athletic performance and injury prevention.  Listen in to learn the purpose of stretching, how to incorporate dynamic stretching before exercising, and the different psychological aspects of different stretching modalities.  Show Notes: Static stretching before sports [2:31] Purpose and type of stretching [5:15] What is dynamic stretching [9:00] Dynamic stretching and athletic performance [15:08] Injury incidence and dynamic stretching [16:09] How much range of motion (ROM) do we really need? [22:55] Mechanisms of ROM increase [27:15] Mechanisms – balance and proprioception [33:39] Psychological aspects [39:34] How to use different stretching applications [44:04] Links Mentioned: Watch this episode on YouTube Yoga for Athletes Teacher Training Online Dynamic Stretching Overview Connect with Katja Bartsch: Facebook | Instagram | Kalamana Yoga | Yoga Medicine® Online Guest Teacher You can learn more about this episode, and see the full show notes at YogaMedicine.com/podcast-99. And you can find out more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts.

Welcome to BCI Cattle Chat!  Please click on any links below to be taken to sources mentioned in the podcast. Keep an eye out for news regarding the podcast on Facebook, Twitter, and Instagram. 3:10 Industry Inventory Counts: How Does it Impact Me? 10:18 Winter Cow and Bull Management   18:43 Research Round-Up: Maddie Mancke… Continue reading Industry Inventory Counts, Winter Cow and Bull Management, Research Round-Up

In this episode Alex R. Kemper, MD, MPH, MS, FAAP, deputy editor of the journal Pediatrics offers a bird's-eye view of the December issue. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Sophie Balk, MD, FAAP, lead author of the latest policy statement and technical report on preventing harmful noise exposure. For resources go to aap.org/podcast.

Today hosts Tiffany and Katja talk about a topic that always draws a lot of interest: the female menstrual cycle. The pair discuss new research around athletic performance throughout the cycle, offering new angles that go beyond the fluctuations of female sex hormones. They focus on new findings that consider the importance of psychological aspects in this context. Listen in to learn some new perspectives on athletic performance and the female cycle and ways to use yoga to support your menstrual cycle. Show Notes: Assumptions of menstrual cycle-based training [3:51] New research on performance during menstrual cycle (MC) [6:52] Who participated in the study [10:44] What was tested for in the experiment [14:18] Results of the latest research [16:19] Further considerations on inclusion criteria [18:57] The complexity of studying the female cycle [21:24] Performance vs. training [23:38] How yoga can help to work with the MC [25:42] Importance of the nervous system in training [27:12] Limitations of current research [30:43] Individual experience “versus” research [33:03] Links Mentioned: Watch this episode on YouTube Athletic Performance Menstrual Cycle Overview Yoga for Athletes Teacher Training Female Health Yoga Teacher Training Connect with Katja Bartsch: Facebook | Instagram | Kalamana Yoga | Yoga Medicine® Online Guest Teacher You can learn more about this episode, and see the full show notes at YogaMedicine.com/podcast-97. And you can find out more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts.

In this episode Rachel Moon, MD, FAAP, associate editor of digital media for the journal Pediatrics, shares a research roundup from the November issue. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also talk to Jenni Kusma, MD, MS, FAAP, and Jean L. Raphael, MD, MPH, FAAP, about a new policy statement recommending foundational reforms to Medicaid and the Children's Health Insurance Program or CHIP. For resources go to aap.org/podcast.

Nigel Paine and Martin Couzins discuss the six action points taken from Insights Media's Research Roundup report into generative AI.

Today hosts Tiffany and Katja talk tips for keeping calm under pressure. This episode is all about choking up or freezing under pressure, which can apply to so many different situations whether you're a yoga teacher, a presenter, or an athlete. We talk about the mechanisms behind choking under high-pressure situations and offer tools that you can use to prepare yourself for situations where you might encounter hyperarousal, distraction and excessive self-focus, which can get in the way of your performance. Listen in to learn what is happening in your body when you face pressure and what you can do to mitigate the negative effects of performance jitters. Show Notes: Mechanisms behind choking under pressure [5:59] Tools to counter hyperarousal [11:21] “Pressure as privilege” mindset [18:50] Tools to prepare for distractions [21:47] Pre-performance routines for athletes [27:48] Reframing internal worries [31:41] Interventions for paralysis by analysis [33:55] Minimizing explicit knowledge of specific movements [37:47] Links Mentioned: Watch this episode on YouTube Calm Under Pressure Overview Connect with Katja Bartsch:          Facebook | Instagram | Kalamana Yoga | Yoga Medicine® Online Guest Teacher You can learn more about this episode, and see the full show notes at YogaMedicine.com/podcast-93. And you can find out more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts.

Even with unanswered questions about a potential slowdown, the Q4 economy is largely firing on all cylinders. Commercial real estate continues to navigate a unique correction, while rising stock/bond correlation helps corporate credit shine. Can the growth continue? Join Lara Rhame, Chief US Economist, Robert Hoffman, Managing Director, Credit Wealth Solutions, and Andrew Korz, Director, Investment Research as they dive into their outlooks for commercial real estate, corporate credit and macroeconomic trends. 

We're doing our first research round up. This is where Jerred and Joe each pick 2 studies that we find relevant for garage gym athletes and brief them without the other having looked at the study.

In this episode Lewis First, MD, MS, FAAP, editor-in-chief of Pediatrics, is back for “First Up.” He offers a bird's-eye view of what's in the October issue of the journal. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Sherri Zorn MD, FAAP, about preventing HPV cancers by starting HPV vaccination at age 9. For resources go to aap.org/podcast.

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research advances in treating non-small cell lung cancer, small cell lung cancer, and mesothelioma.  Dr. Charu Aggarwal is the Leslye Heisler Associate Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania's Perelman School of Medicine in Philadelphia, Pennsylvania. She is also the 2023 Cancer.Net Associate Editor for Lung Cancer. Dr. Melina Marmarelis is an assistant professor at the University of Pennsylvania, the Medical Director of the Penn Medicine Mesothelioma Program, and the co-director of the Molecular Tumor Board at the University of Pennsylvania. She is also the 2023 Cancer.Net Specialty Editor for Mesothelioma. Dr. Kristin Higgins is a radiation oncologist, Professor and Vice Chair in Clinical Research in the Department of Radiation Oncology at Emory University School of Medicine and medical director of radiation oncology of The Emory Clinic at Winship Cancer Institute's Clifton campus location. She is also a 2023 Cancer.Net Advisory Panelist for Lung Cancer. You can view disclosures for Dr. Aggarwal, Dr. Marmarelis, and Dr. Higgins at Cancer.Net. Dr. Aggarwal: Hello and welcome to this Cancer.Net Research Round Up podcast. Today, we will be talking about the latest research from the Annual Meeting of the American Society of Clinical Oncology from June 2023, and I'm joined today by 2 experts in the field of lung cancer. Before I introduce them, I'd like to introduce myself. I'm Dr. Charu Aggarwal. I'm an associate professor for lung cancer excellence at the University of Pennsylvania's Abramson Cancer Center. I'd now like to introduce Dr. Melina Marmarelis. Dr. Marmarelis: Hi, so happy to be here. I'm Melina Marmarelis. I'm an assistant professor at the University of Pennsylvania and the medical director of the Penn mesothelioma program. Dr. Aggarwal: And Dr. Kristin Higgins. Dr. Higgins: Hi, everyone. I'm Kristin Higgins. I am a thoracic radiation oncologist at Winship Cancer Institute of Emory University. I'm a professor and vice chair for clinical research for radiation oncology. Dr. Aggarwal: Fantastic. So today, we'll talk about relevant research as it applies to practical implications in the clinic for practitioners, but most importantly, patients with lung cancer. I'd like to start off by discussing 2 key studies, and I would love for perspectives from our faculty here. The first study I want to highlight is the ADAURA trial. This is a trial that has already sort of changed practice in most recent years when the study was presented at the Annual Meeting of the American Society of Clinical Oncology in 2020, but we have new updates on this study as of 2023. So, in brief, this was a study that looked at the value of administering an oral pill called osimertinib that is a tyrosine kinase inhibitor against the EGFR, or the epidermal growth factor receptor, in patients with non-small cell lung cancer. We know that non-small cell lung cancer is quite a heterogeneous disease with some subsets of patients having mutations that may render them increasingly sensitive to the effects of these tyrosine kinase inhibitors. In fact, these pills have been used in the metastatic setting for several years based on an improvement in overall survival. What the ADAURA study tried to do was ask the question if this pill would add an incremental advantage after receiving curative-intent surgical resection in those with early-stage lung cancer. So this study enrolled patients with stage IB to IIIA non-small cell lung cancer after surgical resection and focused only on those patients that had sensitizing EGFR mutations with EGFR exon 19 deletion or L858R mutations. Patients could receive chemotherapy after having the surgery and then were basically randomized into 2 groups, one of whom received osimertinib at a dose of 80 milligrams once daily for a total of 3 years. Patients were followed up for recurrence. We already know from the earlier results that patients who received osimertinib had a better chance of delaying the recurrence of disease. However, what we found at the Annual Meeting this year is that the administration of this osimertinib also improved overall survival, which is really what we all look for in the oncology world. If you're administering a therapy, especially for a long duration, we want to be able to see a survival benefit, and that's what we saw. In fact, in patients who received osimertinib, there was a 49% less likelihood of dying from lung cancer compared to those who did not receive osimertinib. This, I think, is practice-affirming. It may not be practice-changing because some of the practitioners started using osimertinib after its FDA approval in December of 2020, but I think it just confirms our practice as it delivers an overall survival advantage in these patients. One thing that's increasingly important is to identify patients who have this mutation, so now we have efforts underway locally as well as nationally to perform molecular genotyping on all patients with lung cancer so that we can adequately and appropriately treat those with early-stage lung cancer following curative resection or following surgery. Melina and Kristin, what are your thoughts? Dr. Marmarelis: Well, I think these results are really important because it did, as you say, affirm kind of what we're already doing, but I think the most convincing part of this for me is the prevention of spread of disease to the brain. This is not comparing osimertinib after surgery versus osimertinib ever, which I think is a difficult part about interpreting this trial. But I think the fact that it prevented disease from going to the brain is really meaningful to everyone, to patients, to the physicians that are caring for them, so I think that's a really important endpoint. Dr. Higgins: I agree with Melina. I think this is really exciting for our patients. It's exciting to have more treatment options for early-stage lung cancer. I think patients that are diagnosed with early-stage lung cancer are highly motivated to do everything they can to improve their likelihood of being cured. So I tend to have a lot of conversations about side effects and toxicities with patients that have questions and are sort of wondering how it will affect their quality of life, and of course, that is an important piece of it because patients that do have curable lung cancer are probably starting off with a better overall quality of life, but I think generally speaking, our patients have tolerated it well. I'm also kind of excited from a radiation oncology point of view. We treat patients with stereotactic body radiation therapy [SBRT] that are medically inoperable. And we have another trial with a cohort looking at osimertinib for those patients that have EGFR mutations, too, and that's ongoing, again, applying the same concept of trying to really use these SBRTs that work really well in the advanced setting, moving them into earlier stages of disease to help us care for more patients. So overall, I think it's really exciting, and I think it's a huge win for the clinical research community. Dr. Aggarwal: Well, that's wonderful. And I think this certainly advances the field as this is the first targeted therapy approved for patients with early-stage non-small cell lung cancer. I should add that AstraZeneca, the company that makes this drug, has provided institutional research funding to my institution, and I also serve as an advisor to them, but I was not involved personally in the research of this clinical trial. I'd like to move on but stay within the field of early-stage lung cancer and talk about another study called the KEYNOTE-671 study, and this is important because it really applies the idea of using immunotherapy before and after surgical resection in patients with early-stage lung cancer. Just to give a little bit of background to our listeners, we now have 3 approvals for the use of immunotherapy in patients with early-stage lung cancer. Two of those are in the adjuvant setting, meaning that if a patient undergoes surgical resection or surgery for early-stage lung cancer, they can receive either atezolizumab or pembrolizumab following that surgery, and that has been shown to improve outcomes in terms of reducing the chances of recurrence. We also have another approval, which is the third approval in early-stage lung cancer, where 3 cycles of chemotherapy and immunotherapy are administered prior to surgery, also called as the neoadjuvant chemo-immunotherapy approach. This drug that has been approved in combination with chemotherapy is nivolumab, and this approval came from a clinical trial called CheckMate 816 that showed both that patients who received this neoadjuvant chemo-immunotherapy approach had a higher proportion of patients who had complete response or pathologic complete response in their tumors at the time of surgery and also showed that the chances of the disease coming back after surgical resection was much lower amongst those that had received this intervention. The current study, the KEYNOTE-671 study, builds upon this concept and adds both a before-surgery intervention as well as an after-surgery intervention. So what this study did was it enrolled patients with early-stage, stage II to IIIB non-small cell lung cancer, and patients in the intervention arm received 4 cycles of chemotherapy in combination with pembrolizumab, underwent surgery, and then received immunotherapy with pembrolizumab for up to 13 cycles. Patients in the control arm received only chemotherapy prior to surgery and then placebo for up to 13 cycles after. This was a large study with about 786 patients randomized, and what we found was that those patients that received the intervention had a much higher likelihood of remaining disease-free or event-free following surgical resection as well as in the early analysis, an improvement in overall survival with about a 27% reduction in the risk of death. So I do think that this is the first study that shows us that use of both neoadjuvant as well as adjuvant. So sort of this perioperative approach of using immunotherapy before and after surgical resection can actually lead to improved outcomes. This is ultimately what we want for our patients, improvement in overall survival, improvement in cure rates, etc. The study has been silent on the use of radiation therapy, although it has gone into details in terms of the kinds of surgery that was done. Kristin, what are your views about this? Dr. Higgins: I think postoperative radiation after resection for non-small cell lung cancer has sort of started to fall out of favor because of the Lung ART trial that was published in Europe, a randomized phase III trial that showed no differences in disease-free survival or overall survival. And that's not to say that there aren't more study questions on ways to give it safer and ways to incorporate radiation in with the chemo-IO approach, and there are some novel ways to do that, and we're going to see some data presented at the World Lung Cancer Conference looking at some of those novel approaches. But standardly, when patients receive neoadjuvant chemo-immunotherapy followed by surgery, we typically would not offer radiation. There are instances, though, when patients have positive margins, for example, and in that situation, it's sort of a discussion on a case-by-case basis. But ideally, we're hoping that most of these patients that go to surgery are able to get a complete resection, and that's really the key component of the decision-making for deciding if patients are eligible for this approach. Dr. Aggarwal: I agree. Melina, any additional thoughts on this trial? Dr. Marmarelis: I think it's an exciting trial for the reasons that you mentioned. I think it does bring up a number of questions about whether both neoadjuvant and adjuvant immunotherapy are needed. I tend to like the idea of having immunotherapy present when the tumor is present before surgery, so I like kind of having that on board, but I think we still don't know which is more important. Dr. Aggarwal: So it certainly raises many more questions, which hopefully will be answered in the future. KEYNOTE-671 trial was conducted by Merck that produces the drug Keytruda, or pembrolizumab. We have received institutional research funding for other trials. I was not personally involved in this clinical trial. I do serve as an advisor for Merck. I think we'll bring you more research from the ASCO Annual Meeting. And I'll turn it over to Dr. Marmarelis to discuss some more exciting research. Dr. Marmarelis: Thanks, Charu. So perhaps it's not surprising that one of the exciting things I picked from ASCO has to do with mesothelioma. And I just want to put into context a little bit about why this trial was important. This is IND227. It was a cooperative group trial done across Canada, France, and Italy, and this was chemotherapy plus or minus pembrolizumab in patients with pleural mesothelioma that did not undergo surgery. So this was their first treatment, and they were not undergoing surgery. And the reason this trial was important is that in the last few years, we had results from CheckMate 743, which was looking at IPI/NIVO, so a combination of immunotherapies versus chemotherapy. And there was an improvement in survival for those that received double immunotherapy, and that improvement was most pronounced in the non-epithelioid population, which is actually a smaller subset of pleural mesotheliomas. And so as we've seen in the lung when we look at immunotherapy versus chemo, it raises the question of whether combination immunotherapy plus chemotherapy would actually be better for all and, in particular, for all histologies in pleural mesothelioma. So this was looking at that concept. It took the standard chemotherapy, carboplatin-pemetrexed or cisplatin-pemetrexed, and then combined it with one immunotherapy, so slightly less than the combo immunotherapy seen in CheckMate 743, and that was pembrolizumab. And what they saw was that there was a small overall survival improvement in the group that got pembrolizumab. Again, that was most pronounced in patients in the non-epithelioid group, so those with sarcomatoid or biphasic histology. And this is really a prelude to several other trials that are coming out in mesothelioma, namely the DREAM3R trial, which is looking at chemotherapy plus or minus durvalumab. That control arm also includes IPI/NIVO, so that will be really important to be able to compare those, and then also the BEAT-meso trial, which is looking at chemotherapy-immunotherapy but also with an anti-VEGF agent, bevacizumab. So I think this was an important trial. It's a little bit of proof of concept, but there's still a lot that we're looking forward to. It's not quite practice-changing in the clinic, although I think it's certainly an option that people are using, but I'm looking for more data going forward. Dr. Aggarwal: It's incredible to see how far we've come in mesothelioma within the last decade. We are introducing immunotherapy. We're introducing novel agents in the first-line setting. Dr. Marmarelis: The other trial that I was interested in was KEYNOTE-789, which is looking also at patients with EGFR mutations and those that had the original osimertinib as their first-line treatment or another tyrosine kinase inhibitor and then had disease progression on that TKI. And this is an area of huge need. We have patients that do really well on targeted therapies, and then they have disease progression, and we're looking for additional targeted options, but we're also looking for effective chemotherapy options. And one of the questions that has risen from this is whether there's a role for immunotherapy. We know that immunotherapy alone in patients with EGFR mutations is not very effective when you look at a broad population, but in combination with chemotherapy, it's possible that it can add some benefit. So this trial looked at those that had EGFR mutations, had disease progression after a targeted therapy, and then it randomized them to chemotherapy plus or minus pembrolizumab, so chemotherapy plus or minus immunotherapy, and interestingly, it had no difference in the progression-free survival or the overall survival. So the 2 arms were really similar in terms of outcomes. There was also no difference in the overall response rates of the amount that the drug actually shrinks the tumor. So it really doesn't look like immunotherapy is adding much to chemotherapy for these patients. I think we still need to look a little bit closer because there are probably some patients with EGFR mutations that could benefit from immunotherapy, but we're really not very good at identifying those. One of the questions that comes up in this space is whether to add anti-VEGF treatment in addition to chemotherapy and immunotherapy. So there are some upcoming trials looking at that. Dr. Aggarwal: I think this was a trial that was actually very important and again, practice-affirming that this idea of continuing chemotherapy without adding immunotherapy, patients are not losing much. In fact, they're not gaining anything by adding immunotherapy as shown in this clinical trial. I think continuing immunotherapy, so continuing osimertinib, may be important in this setting also because we know that osimertinib can cross the blood-brain barrier. It can provide that CNS [central nervous system] protection. Dr. Marmarelis: Yeah, I think that's a great point that the comparison here is not chemotherapy plus osimertinib. It's chemotherapy alone. So I agree that the control arm is not quite what some of us do. I agree. I do the same as you do. I also just want to mention that the KEYNOTE trial and the previous trial about mesothelioma used pembrolizumab, which is made by Merck. We have received institutional funding, and I've served as an advisor as well as received honorarium from Merck.   Dr. Aggarwal: Melina, those were 2 very important studies and certainly, I think, answer some very relevant questions in clinic in the management of patients with EGFR-mutant lung cancer, for example. And then I think we look forward to more practice-changing data in mesothelioma. Kristin, I would love to hear research from ASCO from you. What caught your interest? Dr. Higgins: So I have a special interest in small cell lung cancer. And I think there was one important small cell lung cancer trial that I wanted to review with everyone. It was SWOG S1929. And SWOG is the Southwest Oncology Group, and it's a cooperative group that conducts clinical trials in cancer funded by the National Cancer Institute. And this is a randomized phase II trial of atezolizumab and chemotherapy followed by randomization to continuing the maintenance of atezolizumab with a PARP inhibitor. Now, we know from prior data that PARP inhibition is attractive for small cell lung cancer because PARP is expressed frequently in small cell lung cancer, and there is a biomarker called Schlafen-11 that preclinical data and prior data has shown can predict response to PARP inhibition. And this trial was sort of a proof-of-concept trial, a small, randomized phase II trial testing whether or not that Schlafen-11 biomarker could be used to direct therapy. Now, in this trial, there were 309 patients that were registered. They then had to have their tumor samples sent for central testing for the Schlafen-11 expression. One thing that I think is important to bring up is that in small cell lung cancer, there's this belief that it's really hard to get tissue samples from small cell lung cancer and it's a difficult thing logistically because it's just a lot harder to access these tumors. But interestingly, in this trial, 80% of patients had tumors that were evaluable for the biomarker, and the median time to the test result was only 7 days. So patients were able to get their tumor tested, get it sent out, get results in a rapid manner, and then be randomized based on these results. The primary endpoint for this trial was progression-free survival, and the primary endpoint was met. Progression-free survival was 4.2 months versus 2.8 months. Now, I think many people will say the magnitude of benefit here is not very much, but it's small cell lung cancer, and we don't have a lot of positive trials in this space, and we also don't have many trials that have used a biomarker to direct therapy. So I think for those reasons, it's really exciting to see these results. It was also conducted within a cooperative group with multiple different sites across the United States, and the fact of the matter is that we can do trials like this in small cell lung cancer patients, and I think it will sort of serve as a precedent for future trial design. Now, the overall survival for the trial is still premature. It didn't look that much different with the PARP inhibitor, but that doesn't mean that, again, things could change with more follow-up. And I really like the approach of this trial design, and I'm excited to see biomarker-driven trials in small cell lung cancer. Charu and Melina, what do you guys think about this study? And what do you think about our small cell lung cancer patients and our ability to conduct future trials like this? Dr. Aggarwal: I think this is certainly an advance. As you pointed out, Kristin, it shows us that we can conduct trials in the space. I think it offers a lens into the potential of personalized therapy in small cell lung cancer, which has eluded us for a very long time. The standard of small cell lung cancer has not changed significantly for a very long time, so I think this is very exciting and can't wait to see more things come in the future. Dr. Marmarelis: Yeah, I agree. I think we've always been asking for additional biomarkers, especially in such a difficult disease like small cell. And so this is really exciting to see potential biomarkers and that it was feasible to actually pose that question and study it. So that part's really exciting. Dr. Higgins: Great. And I should also say I was not involved in the study, and I'm not associated with any of the pharmaceutical companies that were involved in the study for S1929. And the final study that we wanted to talk about was the phase III LUNAR study, and this is sort of a different type of trial in the setting of advanced non-small cell lung cancer. It was studying tumor treatment fields with standard of care in metastatic non-small cell lung cancer after progression with platinum-based therapies. And first, I just want to step back and explain what tumor treating fields are. Tumor treating fields are applied to a patient with a transducer that's placed on the skin, and what it does is it applies an electrical field, and that disrupts mitosis when the cancer cells are trying to divide. And the mechanism of cell death is a little bit unclear. There are sort of many mechanisms that are postulated, one of which is immunogenic cell death, but we don't really know, I think, what's happening. But there have been studies that show improved results with tumor treating fields and other diseases. For example, particularly in glioblastoma multiforme, tumor treating fields are used in combination with surgery, radiation, and temozolomide (Temodar). So it's something that's being used in other disease sites, and this is some of the early data that we've seen in metastatic non-small cell lung cancer. And so in this trial, 276 patients were randomized to tumor treating fields plus standard of care or standard of care alone. Now, I should mention that this trial began enrolling patients in 2016, and so the standard of care was very different. After platinum-based therapies, the standard was considered docetaxel. Of course, platinum-based therapy alone for frontline treatment of advanced non-small cell lung cancer is also not the standard of care anymore. And so I think with that in the background, it does make interpretation of these results somewhat difficult, and that's probably the major caveat to this study. But nonetheless, patients were randomized, 276 patients. The primary endpoint of the study was overall survival. They were looking at progression-free survival and overall response rates as secondary endpoints as well as overall survival in patients that received immunotherapy versus just chemotherapy alone. And the trial was positive. Overall survival was improved. The median overall survival was 13.2 months for patients that received tumor treating fields with standard of care versus 9.9 months for standard of care alone. If you look at 3-year survival, it was 18% versus 7%. I think this is a new type of therapy for our patients with non-small cell lung cancer. It is somewhat of a difficult thing to wear the transducer, and you have to wear it for many, many hours. So that is one thing that I think can be difficult for patients that are using this treatment, but nonetheless, it is something new for advanced non-small cell lung cancer. I do know that the technology of tumor treating fields is being studied in other settings for non-small cell lung cancer, for stage III non-small cell lung cancer, for example, and also in the frontline setting. I think this trial kind of speaks to the fact that the landscape of advanced non-small cell lung cancer is changing so rapidly, and when we're studying something novel, we have to make sure that we make these trials feasible for enrollment so that we can get them completed rapidly, and we can get a readout and it doesn't become obsolete based on this shift in the standard of care. So I think it just really kind of drives home that we need to make sure that we're taking that into account with trial design. It's not standard of care changing right now, but it'll be interesting to see how the data evolves over time. Melina, I'm interested to hear your point of view because I know that these can be used in mesothelioma, maybe not that frequently. What is your experience with tumor treating fields, if any? Dr. Marmarelis: Tumor treating fields are approved as a device in pleural mesothelioma in the first-line setting in combination with chemotherapy. They have been used off-label in other settings, but that's the device approval. The trial that looked at tumor treating fields in mesothelioma was a single-arm trial, so there was no control arm, and it was really actually just looking at the safety of the device. So I have not used it personally in mesothelioma, although I know of patients and I know of real-world studies looking at its use, and I think it's potentially an interesting modality of treatment, especially in combination with immunotherapy, given that it really doesn't have a lot of additive toxicity. But I think the question is really, which patients are benefiting from it, and which patients are able to actually wear the vest in the case of mesothelioma? Dr. Higgins: Yeah. Any thoughts, Charu? Dr. Aggarwal: I agree, and I think this is going to be largely driven by patient experience. I think this is going to be quite onerous to wear this, carry the suitcase, so I would be very interested in patient reported outcomes as well as patient experiences and stories, which will really drive our use here. Dr. Higgins: Yeah, that's a great point. I should say that this trial was sponsored by Novocure. My institution does have other Novocure studies underway, and we receive research funding, but I was not involved in the study, and I did not personally receive any research funding. Dr. Aggarwal: Thank you, Kristin. This has been a wonderful review of practice-changing and some promising research that came out of the ASCO Annual Meeting. I hope our listeners enjoyed it, and we'll be sure to update you with the next annual research conference. Thank you, everyone. ASCO: Thank you, Dr. Aggarwal, Dr. Marmarelis, and Dr. Higgins. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research in symptom tracking and improving health equity in childhood cancer. First, Dr. Fay Hlubocky discusses research on new ways of tracking symptoms in order to improve outcomes in people with cancer. Dr. Hlubocky is a licensed clinical health psychologist with an expertise in psychosocial oncology and a health care ethicist at the University of Chicago. She is also the 2023 Cancer.Net Associate Editor for Psychosocial Oncology. You can view Dr. Hlubocky's disclosures at Cancer.Net. Dr. Hlubocky: Welcome. I'm very glad that you are able to join us today. My name is Dr. Fay Hlubocky. I am honored to serve as the Cancer.Net Associate Editor for Psychosocial Oncology. I'm a clinical health psychologist specializing in psychosocial oncology at the University of Chicago Medicine. Psychosocial oncology centers on addressing the emotional needs of patients, caregivers, and clinicians from clinical research and educational perspectives. I have no conflicts of interest to report today. Today, we will discuss research on quality cancer care that was presented at the 2023 ASCO Annual Meeting. The theme for this year's meeting selected by the 2022-2023 ASCO President, Dr. Eric Winer, required all attendees to critically examine how interactions between clinicians and patients have changed over the years. “Partnering with Patients: The Cornerstone of Cancer Care and Research” centered on the need to observe what has been improved, what has worsened, and what can be achieved to make interactions between clinicians and patients better. The extraordinary quality and psychosocial care research presented at this meeting honored and fulfilled Dr. Winer's theme. For example, one session centered on the use of novel informatics technology to carry out research and care in the cancer clinical setting. This session, entitled, “Implementing Innovation Informatics-based Technologies to Improve Care Delivery and Clinical Research,” illuminated the current research progress of implementation for emerging information technology innovations in cancer care delivery. This session was designed to help oncologists and cancer care team to evaluate whether and how to integrate these innovations into their own clinical context. One outstanding research presentation was by Dr. Monika Krzyzanowska from Toronto's Princess Margaret Hospital called, “Implementing ePROs in the Real World Oncology Practice,” where she emphasized the importance of not only identifying and monitoring patient-reported outcomes or specific symptom burdens such as pain, fatigue, depression, or anxiety in the clinic, but yet they need to be monitored across the patient's treatment course well into survivorship at different time points, including at home. Therefore, there is a need for a standardized approach of identifying symptoms from patients because as Dr. Krzyzanowska said, patients forget to report even distressing symptoms, and clinicians at times are not always prepared to obtain these symptoms from patients. Historically, in the clinic setting and as patients receive treatment in the chemo suite, we have moved from paper and pencil clinical assessments to the use of robust assessments via electronic medical records systems in both the clinic and subsequently while patients are at home. She reported that more than 10 randomized clinical trials examined the benefits of remote monitoring for patients who undergo mostly systematic therapy with consistent improvements in both symptom control and other outcomes, including survival. She provided very robust real-world and life examples of successful implementation of patient symptom monitoring systems. For example, these have shown consistently that there's a need of improvements in symptom control, but improvement with the other outcomes. To date, she reported on several ongoing initiatives, including a large oncology community practice in Arkansas, who reported on their preliminary initial experiences with an assessment platform of 1,000 patients on systemic therapy who reported symptoms on a weekly basis. This team identified a very high recruitment rate of 79% with amazing retention rate at 88% at 6 months, dropping to about 67% at 12 months. Another real-world implementation example she noted is the work by the National Cancer Institute-funded SIMPRO consortium project, where 6 cancer centers evaluate symptom burdens in 2 different clinical scenarios: patients receiving systematic therapy and patients recovering from surgery. Here, patient data and symptoms are collected via an EMR-based E-system to readily respond to patient needs. The preliminary data and a whole host of research presentation centered on SIMPRO at the Annual Meeting showed that it was feasible, but yet a dynamic design is needed to address any operational and technical barriers for optimal implementation. Ideal partnerships between oncologists, cancer teams, patients, administrators, as well as the IT team is needed for optimal implementation as Dr. Krzyzanowska emphasized. Once these interventions are implemented, a study of sustainability of consistent patient reporting with adequate follow-up by team members, such as nursing, is important for long-term practice success. Finally, she reports that the future research of ePROs evaluation will involve novel approaches, such as clinical teams that will need to gather more complex data, including the use of dynamic approaches, such as wearable technologies, machine learning to address barriers and to improve the overall patient experience. In fact, a specific example of this type of research which reported on both the benefits and barriers centering on ePROs trials at the ASCO Annual Meeting included a very large randomized controlled trial by a Danish team led by Dr. Blechingberg Friis to evaluate the effects of remote symptom monitoring of patients with advanced lung cancer completing induction treatment in a Danish setting. Patients were randomized 1-to-1 to a remote symptom monitoring or an intervention arm added to standard care or just a standard care arm alone. Patients in the intervention arm completed an electronic questionnaire from home covering 13 common symptoms related to lung cancer. A severity alarm or threshold was applied to each question where elevated scores were sent to a clinical nurse for intervention. Weekly compliance to symptom monitoring during that first year was 82% with an intention to monitor population. Although remote monitoring did not significantly improve clinical outcomes for all patients with advanced lung cancer in the Danish population, the benefits were identified for a subgroup of patients not receiving maintenance therapy and for those with a prior organizational experience with ePROs monitoring, which may be essential for improving outcomes of symptom monitoring. In summary, as indicated by the researchers and Dr. Krzyzanowska, more research is needed using these novel approaches to determine the best ePROs platforms for the practice setting. Yet these approaches are critical to improve the overall quality of life of patients, especially during treatment, after surgery, and well into long-term survivorship. In summary, patients should be encouraged to discuss symptom burdens from physical to emotional with their oncology team and to use this technology. It was an honor and pleasure to present this research to you today. Thank you for listening to this brief summary of new research and quality care from the 2023 ASCO Annual Meeting. Best wishes. ASCO: Thank you, Dr. Hlubocky. Next, Dr. Daniel Mulrooney discusses new research on improving health equity in children, adolescents, and young adults with cancer. Dr. Mulrooney is an Associate Member in the Division of Cancer Survivorship at St. Jude Children's Research Hospital. He is also the 2023 Cancer.Net Associate Editor for Pediatric Cancers. You can view Dr. Mulrooney's disclosures at Cancer.Net. Dr. Mulrooney: Hello, my name is Dr. Dan Mulrooney from St. Jude Children's Research Hospital. I am the Deputy Director of the After Completion of Therapy Clinic at St. Jude and primarily care for survivors of pediatric cancers. Like previous meetings, the 2023 ASCO Annual Meeting was quite busy and full of research presentations sharing knowledge and advances in cancer treatment and care. Nearly 100 abstracts were presented concerning children with cancer, and these ranged from early studies of new agents to treat relapsed or refractory cancers, some of the most difficult to cure, to molecular profiling of tumors, to late outcome studies characterizing late effects, improved surveillance methods, and potential preventive treatments for adverse effects after cancer therapy. Now, while all of these were particularly exciting to hear and learn about, this year's meeting also had an important focus on addressing equitable cancer care for all children diagnosed with cancer. When a child is ill, it affects the entire family and can be very stressful for all concerned and may especially place a burden on families economically, particularly for those who may live in underserved areas or lack resources when their child is first diagnosed with cancer. Importantly, financial stresses can increase over the course of treatment. And unfortunately, studies have shown that outcomes are inferior for children from low socioeconomic backgrounds compared to those from other, more resource-filled backgrounds, despite the same protocol-driven therapies. Today, I'd like to highlight some of these presentations. Please note, I do not have any relationships to disclose related to any of these studies. A study with the goal of determining the ability to assess social determinants of health in upfront treatment protocols was conducted by the Children's Oncology Group, or COG, a large consortium of pediatric oncology centers that runs national and international trials to advance the treatment of children with cancer. Historically, the COG was only collecting information on race, ethnicity, insurance, and ZIP code. Collecting information on household material hardship may provide information that might be addressed and modified and help improve the treatment of children with cancer. However, before this study, it was not clear if parents would be willing to share this information with their child's treatment team. Investigators asked parents of children newly diagnosed with neuroblastoma and enrolling on the COG study ANBL1531 to complete a survey about where they live, their household income, and their access to stable food, housing, utilities, and transportation, which were called “measures of household material hardship.” Investigators also asked about access to social supports. The surveys were administered with paper and pencil and in the primary language of the participant. 360 of 413 eligible participants, or 87%, opted to complete the survey across 101 different treating sites. 89% of the surveys were completed within 11 days of enrollment. Most participants answered all of the questions. In fact, less than 1% left some questions unanswered. Importantly, nearly one-third of participants reported having household material hardship, of which 55% reported a single insecurity around food, housing, utilities, or transportation. And 45% reported multiple hardships in these domains. These investigators are planning to extend this work and evaluate associations with cancer outcomes in the hopes of better understanding the mechanisms of these disparities and developing interventions to address these issues in future COG studies. This study raised important issues about what can be done to improve or minimize household material hardship for families of children with cancer. In a pilot study conducted by the same study group at the Dana-Farber Cancer Institute and in collaboration with the University of Alabama, investigators studied the feasibility of a randomized intervention providing transportation and groceries to low-income pediatric oncology families. To be eligible, participants had to be less than 18 years of age at diagnosis of cancer and living in a household that screened positive for food, housing, utility, and/or transportation insecurity, the measures of household material hardship, and those who would be receiving at least 4 courses of chemotherapy. Participants were treated at the Dana-Farber Cancer Institute or the University of Alabama between May 2019 and August 2021, and were randomized to receive the intervention called PediCARE, which provided transportation and groceries versus usual care, and this was conducted over a 6-month period. The main outcome was to test the feasibility of the intervention. Would families participate? And the secondary outcome was to assess what proportion of recipients successfully received the intervention and if they found it acceptable. The total of 40 families agreed to participate and be randomized, and none dropped out of the study. All completed surveys at baseline and at the 6-month follow-up period, suggesting that the intervention was feasible, could be successfully delivered, and was acceptable to families. Now another study from the large Childhood Cancer Survivors Study, or CCSS, assessed the association between the expansion of Medicaid under the Affordable Care Act, or ACA, and Medicaid enrollment among childhood cancer survivors. These investigators linked data from over 13,000 5-year childhood cancer survivors to Medicaid insurance data across the years of 2010 to 2016. Survivors were adults, ages 18 to 64 years old, and all had been diagnosed with cancer prior to age 21 years, between the years of 1970 and 1999. The analyses were adjusted for age, sex, race, ethnicity, income, education, and chronic health conditions. The primary aim for these researchers was to determine any Medicaid enrollment for greater than 1 month in the year. They found that Medicaid enrollment rates increased in states that expanded Medicaid coverage from 17.6% pre-expansion to 24% post-expansion, compared to those states that did not expand pre-expansion and 16.9% post-expansion. Adjusting for other factors, the net enrollment increase was 6.6 percentage points. In the expansion states, the increase was greatest among survivors of leukemia and non-Hodgkin's lymphoma. It was also greater among non-Hispanic Black and Hispanic survivors compared to non-Hispanic White survivors and among those with lower household incomes or a high school degree or less. These investigators now plan to look at associations between Medicaid access and health care utilization and long-term cancer outcomes, such as chronic health conditions and mortality. And additionally, a small study from Stanford University reported a partnership with a community-based nonprofit organization [Jacob's Heart] to improve cancer center-based follow-up for Latinx adolescent and young adult cancer survivors, or AYA survivors. These investigators conducted interviews in the participants' preferred language, with cancer survivors, their parents, and staff from the community organization. They were able to identify important themes around unmet needs for this population, such as challenges with obtaining health care and understanding which providers to see for which health issues, an oncologist or primary care provider, uncertainty about what questions to ask these providers, difficulty adjusting to life after treatment, and understanding the late effects of cancer on the whole family, economically and mentally. For example, issues with parental job loss, financial strain, or impacts on other siblings in the home. However, these investigators also found supportive themes such as gratitude, strength, and support. Addressing these barriers is important for families and communities to promote follow-up after cancer treatment. This study was particularly unique because of its ability to successfully partner with a community organization to reach out and provide opportunities to improve care for Latinx AYA cancer survivors. The studies highlighted here and presented at this year's ASCO Annual Meeting focused on identifying barriers to equitable care for all children diagnosed with cancer and has laid the groundwork for future investigations to address these issues for children and families during treatment as well as after treatment and during survivorship. Thank you for listening to this brief summary of some of the exciting and novel research in pediatric oncology presented at the 2023 ASCO Annual Meeting. ASCO: Thank you, Dr. Mulrooney. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Today hosts Tiffany and Katja hone in on another topic related to pranayama: the science of breathing less. In this episode, we talk about the natural fear of retention of the breath and what we can do to combat this fear. We also connect the dots between concepts like intermittent hypoxic training, breathing less volume, and voluntary hypoventilation and talk about how all those practices may affect breathing gases. Finally, we talk a lot about the application of breathing less in our own practice and how to experiment with it. Listen in to learn where the concept came from, what we can learn about breathing less from other fields of study, and how we can apply that to our yoga practice. Show Notes:  Origins of the concept of breathing less [2:15] The O2 side of the coin - intermittent hypoxia & co [3:45] The CO2 side of the coin - hypoventilation & co [8:15] Unpacking voluntary hypoventilation [13:39] The fear of breathing less [17:00] Breathing less from the yoga lens [24:11] Breath holds and pranayama [27:50] Links Mentioned: Watch this episode on YouTube Yoga Medicine Online Resources: September Monthly Dose – Breathe Life Into Your Practice Less is More: Breath Practice for CO2 Tolerance Breathing Resources Doc Pranayama Yoga Teacher Training Connect with Katja Bartsch:           Facebook | Instagram | Kalamana Yoga | Yoga Medicine® Online Guest Teacher You can learn more about this episode, and see the full show notes at YogaMedicine.com/podcast-87. And you can find out more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts.  

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research in melanoma and health equity. First, Dr. Katy Tsai discusses new research in melanoma. Dr. Tsai is a medical oncologist and Assistant Professor of Medicine in the Division of Hematology and Oncology at the University of California, San Francisco. She is also the 2023 Cancer.Net Associate Editor for Melanoma & Skin Cancer. You can view Dr. Tsai's disclosures at Cancer.Net. Dr. Tsai: Hello. Welcome to the ASCO Cancer.Net Research Round Up. I'm Katy Tsai, an associate professor of medicine and the clinical medical director of the Melanoma and Skin Cancer Program at the University of California, San Francisco. I'm happy to be here today to discuss research on melanoma and skin cancers presented at the 2023 ASCO Annual Meeting. I do not have any disclosures relevant to the studies to be discussed. So, it's always exciting to see the latest research presented at ASCO. One theme in particular that I'd like to highlight in this podcast is recent advances in the field of adjuvant therapy. For the listeners who may not be familiar with this terminology, adjuvant therapy refers to drugs given after surgery to try to decrease the risk of cancer recurrence. Specifically, late-breaking abstract 9505 presented updates from KEYNOTE-716, an adjuvant study of pembrolizumab, or pembro, in patients with resected high-risk stage II melanoma. Late-breaking abstract 9503, which I'll also discuss, presented data from KEYNOTE-942, a pivotal study of a personalized cancer vaccine plus pembrolizumab in patients with resected high-risk stage III and stage IV melanoma. So, let's start with KEYNOTE-716. We've known for some time in our field now that adjuvant pembrolizumab or nivolumab can help decrease the risk of recurrence for patients with resected stage III or IV melanoma. What may not be as well-known, however, is that patients with stage IIB or IIC melanomas, in other words, thicker, ulcerated primary melanomas, even without lymph node spread, actually have a comparable risk of melanoma recurrence compared to patients with early stage III melanomas. KEYNOTE-716 was a large, international phase 3 study that randomized patients with stages IIB and C melanoma to receive either pembro or placebo. The positive results showing improvement in relapse-free survival led to approval of adjuvant pembro in December 2021, but what was presented at ASCO was an update on distant metastasis-free survival. This is obviously an important endpoint for us because ultimately, if someone is going to develop widely metastatic disease, unfortunately, it is a development of these distant metastases that we are concerned about. So what we saw here is that with landmark 36-month follow-up, there was a 41% reduction in the risk of developing distant metastasis in patients who were treated with pembro compared to those who received the placebo. In addition, there was a consistent maintained benefit in relapse-free survival, and importantly, no changes in the side effect profile. These are important data because I believe it is practice-changing in the sense that this is a population of patients who historically might not ever have been referred to medical oncology, maybe just monitored serially with their dermatologists. And this is an option that should be discussed. Ultimately, the risk versus benefit about whether to pursue a year of therapy versus maybe consider treatment only at the time of recurrence is a very personalized discussion between a patient and their treating oncologist, but it is an option that should definitely be offered. So let's move on to KEYNOTE-942. The novel drug being tested in this trial is very exciting. We're calling it “individualized neoantigen therapy.” So this is basically a platform that allows us to develop individualized treatment for someone based on characteristics of their own cancer. This involves taking the actual tumor specimen, genomic sequencing, specifically whole-exome sequencing is performed to try to identify any changes in the DNA. And then through a bioinformatic pipeline, the mutations in the DNA that are thought to be most likely to generate proteins that can be bound within presenting molecules are then identified in the computer program, then synthesized within mRNA. So very similar to the way that COVID vaccines have been made. So this actually becomes the actual drug product. So in this study, patients were randomized to receive either pembrolizumab by itself for a year, which is, as we alluded to earlier, standard adjuvant therapy, but then with the addition of this individualized neoantigen therapy starting with dose 3 and then throughout the rest of the year. So the recurrence-free survival data were actually presented earlier this year at another major conference, AACR [American Association for Cancer Research], and were highly positive. At ASCO 2023, I think what was most impressive about the presented data is that distant metastasis-free survival, so again, a similar important endpoint that we discussed with the other trial, is that the distant metastasis-free survival here was quite impressively maintained. There was a hazard ratio of .35, meaning really a 65% reduction in the risk of recurrence for patients who received the personalized neoantigen therapy plus pembrolizumab. So this is a huge advantage for distant metastasis-free survival in this particular population of patients. What was even more intriguing is that usually when we combine therapies, we tend to see additive toxicity, more side effects. And what was really exciting about this particular trial is that the additive toxicity really wasn't as much as you would expect for giving 2 immunotherapies at the same time. I'll also highlight that even though these results are really exciting within melanoma, that part of the reason this data is so exciting is that it represents a really promising platform for therapeutic development and application in other tumors besides melanoma. So this is definitely super exciting. While perhaps not practice-changing in this moment, it's potentially practice-changing. And I look forward to seeing additional data coming in from planned trials using this particular combination in the metastatic setting in addition to the adjuvant setting. So on the whole, I do think that updates in adjuvant therapy for melanoma were super exciting to see at ASCO 2023. As I mentioned earlier, it's a very large conference. A lot of exciting data being presented. So I do think that other themes to pay attention to as we continue to sort through existing data and look forward to incoming data from forthcoming trials is looking at neoadjuvant therapy. For example, drug given before surgery to try to improve long-term outcomes. For example, at ASCO this year, there was interesting neoadjuvant immunotherapy data presented not for melanoma, but for a different type of skin cancer called squamous cell carcinoma. So that would definitely be another theme to pay attention to in the coming months and years. Thinking about novel combinations, for example, what's new in immune checkpoint inhibitors, we've been used to for a long time referring only to anti-PD1 antibodies, anti-CTLA4 antibodies. What was interesting to see this year were updates in novel combinations, for example, PD1 antibodies combined with LAG3 antibodies. Antibodies against TIGIT. So I think this will be another exciting space to pay attention to both in the metastatic skin cancer setting and in the adjuvant and neoadjuvant settings. Thank you for your time and attention. That concludes my research roundup for melanoma and skin cancers. Thank you. ASCO: Thank you, Dr. Tsai. Next, Dr. Manali Patel discusses new research in health equity. Dr. Patel is a medical oncologist and Assistant Professor of Medicine at Stanford University. She is also the 2023 Cancer.Net Associate Editor for Health Equity. You can view Dr. Patel's disclosures at Cancer.Net. Dr. Patel: Hi, my name is Manali Patel. I'm the Associate Editor for Health Equity for Cancer.Net, and I'm so incredibly excited to present some really amazing work that was presented at our ASCO Annual Meeting this past June in Chicago. Before I start, I do have one disclosure. I will be talking about studies that were presented relating to patient navigation and one study in particular that my group presented looking at community health workers. And so that is a little bit of a disclosure that I would like to address upfront. And now, just to get right started. I thought what was really interesting was the amount of work this year that was presented on disparities in health equity. As in past years, we actually saw quite an influx, probably more so this year than previously, on studies that looked at differing outcomes, inequities in cancer care delivery, describing disparities in terms of receipt of treatment, so if people were receiving treatment. There tended to be a lot of studies that focused on looking at and describing a lot of these disparities. But what I was really impressed by came out from the pediatric colleagues, individuals who are taking care of younger patients, children who are less than the age of 18, and how many of those particular studies were focused on moving from description to actually intervening and making a difference in health equity. And so I want to highlight a couple. There was one that was done out of Dana-Farber, and actually, a multi-site group of authors. So lots of authors from all over the place, but Emily Jones was the lead author. And they described and actually evaluated how they could collect, in the context of clinical trials for children, which is called Children's Oncology Group Trial-- how they could collect social determinants of health data, meaning data that evaluates people's income, transportation, where people live, what kind of work they may do, if they have food and housing insecurity. And what they were able to show is that, by embedding a lot of these data points-- they actually made these data points optional for patients when they came into the clinical trial. And they found high feasibility, meaning lots of people that were signing up to do clinical trials for the Children's Oncology Group Trial were able to complete this extra data, which is extremely important and is a remarkable willingness of individuals to participate in providing this data which is important for their treatment. Along those same lines, Amy Newman from the Children's Hospital of Philadelphia really did a very nice study looking at the feasibility of what they called PediCARE. And it was this intervention that was focused on trying to ensure that people-- again, children less than the age of 18 across 2 different clinics. They evaluated whether PediCARE would help people to receive necessary and important resources as it relates to social and economic needs. And so they screened for food insecurity, for housing insecurity, for people that had difficulties paying for utilities, and transportation security. And then they randomized individuals to either PediCARE or to just usual cancer care. And what they found was that 100% of the people that were randomized to PediCARE successfully received grocery and transportation resources. They felt that it was easier to buy food for their family, and they reported it was easier to get to and from the hospital and that they would be very likely to report and to recommend this intervention to other individuals. And so it really shows how these interventions can move from just describing that housing, food insecurity or problems-- number 1, it starts with the collection of the data, right? What's really important is making sure that we collect this data because we don't currently do that in cancer care. And then number 2, when we actually do collect the data, what are we going to do about it? And it shows that these interventions really do help people to move past their housing and social and economic issues that they may experience into actually receiving care that's important and necessary to improve outcomes. We did see a lot of data reflecting the importance of health insurance and big policies, what I call Big P, which are these national policies, like the Affordable Care Act. And now we've seen, just year after year and including this year, plethora of studies showing how beneficial the Affordable Care Act has been on reducing disparities and improving cancer outcomes overall. We also saw other studies, such as one presented by Dr. Gladys Rodriguez from Northwestern, which looked at disparities in the intensity of care at the end of life amongst patients with gastrointestinal cancers. And the team revealed, across almost 20 years of data in California, that patients were receiving higher rates of what would be considered low-quality care. Now, this is lower hospice use, which we know helps to actually improve survival, lower rates of palliative care use, and greater rates of burdensome hospitalizations. And now, why I think this is particularly important is because this study evaluated what we know is a problem, that there is low-quality care amongst patients from particular racial and ethnic populations, such as Black and Hispanic patient populations, that aren't receiving the right care when they're diagnosed. And then what this reveals is that, even at the end of life, they're perhaps still receiving low-quality care. Another study looked at screening, which I thought was really impressive. It was by Nicole Anne Gay from the UM Sylvester Comprehensive Cancer Center in Miami. And what they evaluated was essentially a quality improvement program to reduce disparities in lung cancer screening. As a lung cancer doctor myself, it's still shocking that fewer than 6% of people that should receive lung cancer screening, meaning a screening test to help us identify and to treat patients with lung cancer-- they aren't receiving lung cancer screening. And so we know that this is a problem overall. They put into place what's called a multi-level, meaning that there were improvements in the electronic health record that they embedded. They also provided patients with navigation, and they also helped clinicians in the primary care clinics obtain information about who should be eligible and which patients should be receiving screening. And what they found was that they were able to move screening rates from 25% improvement completed during the project period from their baseline, which is actually quite impressive. We also saw an interesting study, and actually, just an interesting evaluation, of childhood leukemia survival on the U.S.-Mexico border. And it was a description of how to implement changes by strengthening care partnerships. And so they evaluated and they described the implementation of this program to achieve what they called sustainable high-quality care for children with leukemia. It was done by Paula Aristizabal and was really in a unique border health setting. It was in partnership between the North American and Mexican institutions. And they used what was called the strengthening model developed by the World Health Organization to evaluate specific domains and to try to improve a sustainable program for children with acute lymphoblastic leukemia at a public referral hospital right on the border region. And I thought that that study was particularly interesting because it shows how to be able to use an approach to improve the staffing of a leukemia service, to implement a sustainable training program as well for other clinicians to learn how to provide leukemia care, and then also to try to improve clinical outcomes and funding for patients to receive medications through local partnerships. I thought it was a really fantastic description of how to begin to do this work that is extremely necessary in low- and middle-income nations but also even on our own U.S.-Mexico border. There were also a lot of studies that evaluated the importance of social and economic factors. We know that financial toxicity, which is an unfortunate side effect of cancer treatment and cancer care and a cancer diagnosis overall, is associated with worse outcomes. Financial toxicity means the burdens and costs that arise with having a cancer diagnosis. And now we've seen studies that were presented at ASCO this past year by Dr. Khan, who showed that, within 2 years of diagnosis, are at higher risk for dying after adjusting for many social and also clinical factors. And Dr. Hu also presented data looking at the implications of having a lot of medical debt and death. And what both of these studies showed is that medical debt is associated with having perhaps a lower likelihood of surviving. It does make sense for Dr. Hu's study that one would have a lot of medical debt if they also have a lot of other conditions, but it does begin to shed some light on the fact that there are worse clinical outcomes, meaning people aren't doing as well, depending on how much other medical care expenses they may have. And then finally, one important piece, which I think is really crucial for what's happening now in the way that oncologists may perhaps be able to advocate for payment for services that are important, is looking at navigation studies. Now, this is patient navigators, and that is a very broad topic. And so there were lots and lots of studies that came out at ASCO that evaluated the importance of navigation, including our own work that looked at what happens to veterans after receiving a lay health worker or a navigator to assist with advanced care planning, meaning helping veterans to understand their goals and preferences. And what these studies have shown is that there's actually not only clinical benefit but also, in our own study, that perhaps there may be a survival benefit even 10 years later. It was very wonderful to be at ASCO this past year, and I really hope that you all can look at some of these studies or take away the important and amazing work that's going on in the health equity space. And I thank you for listening to our podcast. ASCO: Thank you, Dr. Patel. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate. [music]

In this episode Alex R. Kemper, MD, MPH, MS, FAAP, deputy editor of the journal Pediatrics offers a bird's-eye view of the September issue. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Joseph L. Wright, MD, MPH, FAAP, about his new role as Chief Health Equity Officer at the AAP. Dr. Wright talks about the AAP Equity Agenda—progress made and next steps. For resources go to aap.org/podcast.

Today hosts Tiffany and Katja take you on a stroll through the breathwork landscape. In this episode, the pair gives an overview of the origins of different breathing practices - covering Eastern traditions from India to China, techniques founded by "psychedelic" transformational and scientific communities as well as practices stemming from Eastern Europe. If you've ever wanted an overview of where Conscious Connected Breathing, Tummo, Resonant Frequency breathing, and Buteyoko came from - this is the episode you've been waiting for. We also discuss the bigger picture of breathwork as a whole and how Pranayama as a very multi-faceted practice fits into it.  Show Notes: Indian breathwork traditions [2:21] Tibetan breathwork traditions [7:57] Chinese breathwork traditions [15:55] Transformational, “psychedelic” breathwork origins [21:06] Scientific origins – Resonant frequency breathing [32:54] Eastern European breathwork traditions [38:34] Links Mentioned: Watch this episode on YouTube Connect with Katja Bartsch: Facebook | Instagram | Kalamana Yoga | Yoga Medicine® Online Guest Teacher You can learn more about this episode, and see the full show notes at YogaMedicine.com/podcast-85. And you can find out more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts.

Today's topic is an interesting one that comes up a lot in the yoga world. In this episode, hosts Tiffany and Katja talk about the latest research and newest findings on the Polyvagal Theory. They discuss the evolutionary biology that Polyvagal Theory is based around, the neuroanatomy that's involved, and assumptions that have been made about this complex aspect of the body. Listen in to learn about the anatomy of the vagus nerve and how Polyvagal Theory is applied in yoga and therapeutic settings. Show Notes: The emergence of Polyvagal Theory [2:58] Evolutionary biology and dorsal vagus [5:50] Sympathetic nervous system [10:35] Ventral vagus [13:40] Nuances of ventral and dorsal vagus, combinations [15:03] Anatomy of the vagus nerve [17:38] Afferent parts of the vagus nerve (from body to brain) [21:24] Efferent components of vagus (from brain to body) [26:50] How researchers look at cardiac function and Polyvagal Theory [33:01] The role of Polyvagal Theory in yoga and therapeutic settings [37:29] Hypotheses about ventral vagus evolution [43:33] Links Mentioned: Watch this episode on YouTube Polyvagal Resources Doc Connect with Katja Bartsch: Facebook | Instagram | Kalamana Yoga | Yoga Medicine® Online Guest Teacher You can learn more about this episode, and see the full show notes at YogaMedicine.com/podcast-83. And you can find out more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts.

The latest research on how to eat less meat, reversing kidney failure, and the connection between stress and our breath

In this episode Rachel Moon, MD, FAAP, associate editor of digital media for the journal Pediatrics, shares a research roundup from the August issue. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also talk to Benson Hsu, MD, MBA, FAAP, FCCM, about a new policy statement on organ donation and transplantation. For resources go to aap.org/podcast.) 

In this episode Lewis First, MD, MS, FAAP, editor-in-chief of Pediatrics, is back for “First Up.” He offers a bird's-eye view of what's in the July issue of the journal. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Kathleen Kieran, MD, MSc, MME, FAAP, who co-authored a new clinical report, Assessment and Management of Inguinal Hernias in Children. For resources go to aap.org/podcast.

Welcome to BCI Cattle Chat!  Please click on any links below to be taken to sources mentioned in the podcast. Keep an eye out for news regarding the podcast on Facebook, Twitter, and Instagram. 3:00 Cattle Preparations for the Fair 8:30 Heat Stress 17:00 Research Round Up Guest Eduarda Bortoluzzi For more on BCI Cattle… Continue reading Preparations for the Fair, Heat Stress, Research Round Up

A Research Roundup including: -AssistGPT -LLaMA multimodal adapter -Meta Voicebox -Text-to-Video -LLM agent teaching weaker AIs -AI art QR code generator   The AI Breakdown helps you understand the most important news and discussions in AI.  Subscribe to The AI Breakdown newsletter: https://theaibreakdown.beehiiv.com/subscribe Subscribe to The AI Breakdown on YouTube: https://www.youtube.com/@TheAIBreakdown Join the community: bit.ly/aibreakdown Learn more: http://breakdown.network/

Today on the NutritionFacts Podcast, we inaugurate a new series that brings you the latest on a variety of topics. Our first Research Roundup includes the benefits of vinegar for blood sugar control, how coffee can impair iron absorption, and what happens to your brain when you eat a meal high in saturated fat.

Today hosts Tiffany and Katja discuss fascia and the immune system. In this episode, learn what role the fascia plays in the immune system and which less obvious components of fascia contribute to this relationship. We also cover why fibroblasts are dynamic participants of immune processes, and how fluid flow versus stagnation play into immune function. Listen in to learn how cells within our fascial system enable communication in our tissues, the pros and cons of mechanical fascial manipulation, and recent research into the possible existence of a fascial microbiome. Show Notes: Introducing fascia and the immune system [1:30] The role of fibroblasts in immune processes [5:05] The importance of fluid flow [16:06] Mechanical manipulation of fascia [26:52] Studying the fascial microbiome [33:37] Yoga to help us understand the body [38:38] Links Mentioned: Watch this episode on YouTube Fascia & Immune System Resources Doc Lymphatics Yoga Teacher Training Myofascial Release Training Functional Anatomy Online Course with Yoga International Connect with Katja Bartsch: Facebook | Instagram | Kalamana Yoga | Yoga Medicine® Online Guest Teacher You can learn more about this episode, and see the full show notes at YogaMedicine.com/podcast-75. And you can find out more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts.

In this episode Alex R. Kemper, MD, MPH, MS, FAAP, deputy editor of Pediatrics, shares a research roundup from the June issue of the journal. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Anna Esparham, MD, FAAP, DABMA, DABOIM, about ways to help children and teens achieve better sleep and why labels on sleep aids are not always accurate. For resources go to aap.org/podcast.